TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
TransMedics Group Stock Up 0.1 %
NASDAQ TMDX traded up $0.18 during trading on Thursday, reaching $143.80. 754,384 shares of the company’s stock traded hands, compared to its average volume of 830,882. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $177.37. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm has a market cap of $4.74 billion, a price-to-earnings ratio of -422.41 and a beta of 1.99. The company’s 50 day simple moving average is $156.09 and its two-hundred day simple moving average is $133.18.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s revenue was up 117.7% compared to the same quarter last year. During the same period last year, the company posted ($0.03) earnings per share. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald initiated coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target on the stock. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. TD Cowen upped their price target on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Robert W. Baird began coverage on shares of TransMedics Group in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 target price on the stock. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $174.30.
Get Our Latest Stock Report on TransMedics Group
TransMedics Group Company Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Articles
- Five stocks we like better than TransMedics Group
- Why Invest in 5G? How to Invest in 5G Stocks
- When Is the Best Time to Invest in Mutual Funds?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Is NVIDIA Stock in a Correction or Consolidation?
- How to Use Stock Screeners to Find Stocks
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.